Engineered Hydroxamic Acids for Zirconium-89 Positron Emission Tomography (PET) Imaging of Prostate Cancer. Positron emission tomography (PET) using a zirconium-89-ligand complex bound to a prostate-specific membrane antigen is used to detect and monitor prostate cancer. The hydroxamic acid-based ligand bound to zirconium has a high affinity towards iron, which can cause metal exchange in vivo and loss of radiotracer. The project will prepare new ligands with a higher specificity towards zirconi ....Engineered Hydroxamic Acids for Zirconium-89 Positron Emission Tomography (PET) Imaging of Prostate Cancer. Positron emission tomography (PET) using a zirconium-89-ligand complex bound to a prostate-specific membrane antigen is used to detect and monitor prostate cancer. The hydroxamic acid-based ligand bound to zirconium has a high affinity towards iron, which can cause metal exchange in vivo and loss of radiotracer. The project will prepare new ligands with a higher specificity towards zirconium over iron, and measure immuno-PET imaging activity. A second series of macrocyclic zirconium-specific ligands will be prepared to establish the relationship between variable water-lipid solubility and pharmacokinetic properties. The results will increase the capability of immuno-PET for prostate cancer detection and improve survival outcomes.Read moreRead less
Detection of infrared-biomarkers for the diagnosis and treatment of canine neoplasia. This research hopes to discover infrared-biomarkers for canine cancers using synchrotron infrared and laser light. Many dog cancers are similar to human cancers so cancerous tissues and cells from dogs make excellent models for human cancer research. This project will provide new insights and technological approaches to cancer diagnosis and treatment.
MRI Molecular Imaging Agents - from fundamental design to In Vivo Applications. Of approximately 60 million magnetic resonance imaging (MRI) procedures performed annually worldwide, around 30 per cent of these use MRI imaging agents. Imaging agents allow the doctors to study blood flow and to identify particular tissue types and diseases. This project will lead to new classes of high-performance imaging agents which offer the prospect of faster more accurate diagnosis.